Evofem Reports Fifth Consecutive Year of Net Sales Growth

Got story updates? Submit your updates here. ›

Evofem Biosciences, a San Diego-based women's health company, reported its fifth consecutive year of net sales growth in 2025, with record net sales of $20.2 million. This was driven by strong performance of its two FDA-approved products, the hormone-free contraceptive gel PHEXX and the single-dose antibiotic SOLOSEC for bacterial vaginosis and trichomoniasis. The company also reduced total operating expenses by 38% compared to the prior year.

Why it matters

Evofem's continued sales growth and cost-cutting measures demonstrate the company's ability to commercialize innovative women's health products and build a sustainable business model in a competitive market. The performance of PHEXX and SOLOSEC highlights unmet needs in contraception and sexual health that Evofem is addressing.

The details

Evofem reported net sales of $20.2 million in 2025, a 4% increase from the prior year, driven by higher wholesale prices and improved gross-to-net ratios for PHEXX, as well as a full year of SOLOSEC sales after its relaunch in late 2024. The company also reduced total operating expenses by 38% to $16.8 million, including a $5.6 million gain from settling trade payables and a $1.9 million non-cash gain from changes in accounting estimates. This resulted in $3.4 million in operating income, compared to a $7.7 million loss the prior year.

• Evofem acquired the SOLOSEC product in July 2024 and relaunched it in the U.S. in late 2024.
• Since October 1, 2025, Evofem has advanced initiatives to lower manufacturing costs for both PHEXX and SOLOSEC by an estimated 55-60%.

What they’re saying

What’s next

Evofem is advancing initiatives to lower manufacturing costs for both PHEXX and SOLOSEC by an estimated 55-60%. The company is also awaiting regulatory approval for PHEXX in the United Arab Emirates, and the review of the SOLOSEC application in the UAE is underway.